480,822 Shares in Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Purchased by Boothbay Fund Management LLC

Boothbay Fund Management LLC bought a new position in Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX - Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund bought 480,822 shares of the biopharmaceutical company's stock, valued at approximately $355,000. Boothbay Fund Management LLC owned about 0.20% of Lexicon Pharmaceuticals as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also recently added to or reduced their stakes in the company. Barclays PLC boosted its holdings in Lexicon Pharmaceuticals by 391.6% during the third quarter. Barclays PLC now owns 193,873 shares of the biopharmaceutical company's stock valued at $304,000 after acquiring an additional 154,436 shares during the period. Geode Capital Management LLC lifted its position in shares of Lexicon Pharmaceuticals by 8.4% during the 3rd quarter. Geode Capital Management LLC now owns 3,523,971 shares of the biopharmaceutical company's stock worth $5,534,000 after purchasing an additional 273,436 shares during the last quarter. Hennion & Walsh Asset Management Inc. boosted its stake in Lexicon Pharmaceuticals by 18.1% during the 4th quarter. Hennion & Walsh Asset Management Inc. now owns 863,255 shares of the biopharmaceutical company's stock valued at $638,000 after purchasing an additional 132,117 shares during the period. Arizona State Retirement System grew its holdings in Lexicon Pharmaceuticals by 34.4% in the 4th quarter. Arizona State Retirement System now owns 62,976 shares of the biopharmaceutical company's stock valued at $47,000 after buying an additional 16,136 shares during the last quarter. Finally, Swiss National Bank increased its position in Lexicon Pharmaceuticals by 34.4% in the 4th quarter. Swiss National Bank now owns 426,600 shares of the biopharmaceutical company's stock worth $315,000 after buying an additional 109,100 shares during the period. Institutional investors own 74.70% of the company's stock.

Analyst Upgrades and Downgrades

LXRX has been the subject of several research reports. StockNews.com started coverage on Lexicon Pharmaceuticals in a research report on Monday, April 21st. They issued a "sell" rating for the company. Needham & Company LLC reissued a "hold" rating on shares of Lexicon Pharmaceuticals in a report on Monday, March 3rd. HC Wainwright reaffirmed a "buy" rating and set a $4.00 price objective on shares of Lexicon Pharmaceuticals in a research report on Friday, March 28th. Leerink Partnrs downgraded Lexicon Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a research report on Wednesday, March 5th. Finally, Leerink Partners restated a "market perform" rating and set a $1.00 price target (down from $2.00) on shares of Lexicon Pharmaceuticals in a research note on Tuesday, March 4th. One analyst has rated the stock with a sell rating, three have issued a hold rating and two have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Hold" and an average price target of $3.67.

Lexicon Pharmaceuticals Price Performance

Shares of LXRX stock traded up $0.02 during mid-day trading on Wednesday, reaching $0.68. The company's stock had a trading volume of 942,765 shares, compared to its average volume of 6,469,782. The firm's 50-day moving average is $0.49 and its two-hundred day moving average is $0.78. The company has a market cap of $244.37 million, a P/E ratio of -0.90 and a beta of 1.07. Lexicon Pharmaceuticals, Inc. has a 1-year low of $0.28 and a 1-year high of $2.45. The company has a debt-to-equity ratio of 0.56, a quick ratio of 7.43 and a current ratio of 7.45.

Lexicon Pharmaceuticals (NASDAQ:LXRX - Get Free Report) last posted its quarterly earnings results on Thursday, March 6th. The biopharmaceutical company reported ($0.09) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.11) by $0.02. The firm had revenue of $26.55 million during the quarter, compared to analyst estimates of $6.48 million. Lexicon Pharmaceuticals had a negative net margin of 4,109.41% and a negative return on equity of 107.38%. On average, research analysts predict that Lexicon Pharmaceuticals, Inc. will post -0.66 earnings per share for the current year.

Lexicon Pharmaceuticals Profile

Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract.